Noskov S M, Shirokova L Iu, Snigireva A V, Parulia O M, Dybin S D
Ter Arkh. 2012;84(8):33-6.
To evaluate the clinical efficiency of using autologous conditioned (activated) serum (ACS) versus hyaluronic acid (HA) in coxarthrosis (CA).
Two groups of patients (n = 54) who were matched for age, sex, and disease duration and had a valid diagnosis of CA were examined. During 3 weeks, Groups 1 and 2 patients received intra-articular therapy with ACS or synocrome forte (Croma Pharma, Sotex), respectively, for 3 weeks. A 12-month follow-up evaluated the magnitude of pain, by using the visual analog scale (VAS, mm), the functional index WOMAC and general health, by applying the EQ-VAS scale.
The only benefit of HA was found to be more functional improvement as detected by the WOMAC index (-21.8%; t = 2.56) at an early (1-month) follow-up. After 3 months, the patients in the ACS group were recorded to have the maximum VAS pain intensity reduction that was 76.5% greater than that (t = 4.31) in the HA group. The clearest advantages of ACS therapy were traced 6 months after treatment.
The use of ACS may be a real alternative to that of HA derivatives in achieving good clinical outcomes in patients with CA. After ACS administration, there was a long-term preservation of achieved positive results.
评估在髋关节炎（CA）中使用自体条件（激活）血清（ACS）与透明质酸（HA）的临床疗效。
对两组年龄、性别和病程相匹配且确诊为CA的患者（每组n = 54）进行检查。在3周内，第1组和第2组患者分别接受关节内注射ACS或synocrome forte（Croma Pharma，Sotex）治疗3周。通过视觉模拟量表（VAS，毫米）评估疼痛程度，应用WOMAC功能指数和EQ-VAS量表评估一般健康状况，进行为期12个月的随访。
仅发现HA的唯一益处是在早期（1个月）随访时，通过WOMAC指数检测到功能改善更明显（-21.8%；t = 2.56）。3个月后，记录到ACS组患者的VAS疼痛强度最大降低幅度比HA组高76.5%（t = 4.31）。ACS治疗最明显的优势在治疗后6个月显现。
在CA患者中，使用ACS可能是HA衍生物的一种切实可行的替代方法，可取得良好的临床效果。注射ACS后，取得的积极效果能长期保持。
